BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with ...

the result of a bid to strike it down filed by BioNTech. The invalidation has come out of the blue for CureVac, which said earlier in the year that the patent court had supported its position in ...

Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which fell below analyst expectations.

BioNTech (BNTX) on Friday announced separate agreements with the US National Institutes of Health and the University of Pennsylvania to settle royalty claims related to sales of its COVID-19 ...

DUESSELDORF, Germany (Reuters) -A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna. In a statement, the court in the city of ...

This COVID-19 vaccine remains BioNTech's primary revenue source for now. However, the company is working with Pfizer to evaluate two vaccines in late-stage testing, one for influenza and another ...

BioNTech is clearly impressed with what it has seen with partner Biotheus' bispecific antibody for cancer, opting to buy the company outright to get full control of the drug. The two companies ...

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platformfor the treatment of advanced cancers With the closing of the ...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T ...